Jean Jacques Bienaime Purchases 10,500 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime purchased 10,500 shares of the company’s stock in a transaction on Friday, June 5th. The stock was bought at an average cost of $19.45 per share, for a total transaction of $204,225.00. Following the acquisition, the director directly owned 43,415 shares of the company’s stock, valued at $844,421.75. This represents a 31.90% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Jean Jacques Bienaime also recently made the following trade(s):

• On Friday, May 15th, Jean Jacques Bienaime purchased 5,000 shares of Immunome stock. The stock was bought at an average cost of $20.70 per share, for a total transaction of $103,500.00.
• On Wednesday, March 11th, Jean Jacques Bienaime purchased 1,000 shares of Immunome stock. The stock was bought at an average cost of $21.55 per share, for a total transaction of $21,550.00.

Immunome Stock Performance

Shares of NASDAQ IMNM traded down $0.22 during trading on Tuesday, hitting $18.39. The company had a trading volume of 1,077,310 shares, compared to its average volume of 1,355,343. The company has a market cap of $2.08 billion, a P/E ratio of -7.73 and a beta of 2.04. Immunome, Inc. has a 52 week low of $7.96 and a 52 week high of $27.65. The business’s 50-day moving average is $21.97 and its 200 day moving average is $21.70.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. On average, research analysts expect that Immunome, Inc. will post -2.06 EPS for the current year.

Hedge Funds Weigh In On Immunome

Institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV purchased a new position in shares of Immunome during the 1st quarter valued at $60,000. Strs Ohio purchased a new position in shares of Immunome during the 4th quarter valued at $64,000. Assetmark Inc. purchased a new position in shares of Immunome during the 3rd quarter valued at $39,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Immunome during the 4th quarter valued at $121,000. Finally, BIT Capital GmbH purchased a new position in shares of Immunome during the 3rd quarter valued at $69,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on IMNM shares. Barclays assumed coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective on the stock. Craig Hallum lifted their target price on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Leerink Partners reduced their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Stephens decreased their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.